BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2019

Jan 11, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2019-01-08

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-08	Common Stock	M	6000	$14.39	Acquired	294290	Direct
2019-01-08	Common Stock	S	1000	$91.144	Disposed	293290	Direct
2019-01-08	Common Stock	S	1599	$91.55	Disposed	291691	Direct
2019-01-08	Common Stock	S	3401	$91.7348	Disposed	288290	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-08	Stock Option (Right to buy Common Stock)	$14.39	M	6000	Disposed	2019-05-11	Common Stock (6000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	181501	Indirect

Footnotes

F1: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018.

F2: The price in column 4 is the weighted average price. The price actually received ranged from $90.51 to $91.45. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F3: The price in column 4 is the weighted average price. The price actually received ranged from $91.51 to $91.60. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F4: The price in column 4 is the weighted average price. The price actually received ranged from $91.61 to $92.22. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F5: Reflects the number of options outstanding after the transactions from this specific stock option grant.